Pioneering Ketamine Treatment for Depression

How did ketamine evolve from an anesthetic to one of the most important mental health treatment breakthroughs in decades? 

In this episode of The Vitals, guest host Dennis Charney, MD sits down with specialists James Murrough , MD, PhD, and Adriana Feder, MD, to explore the science behind ketamine treatment for depression and PTSD—and why it may offer hope for patients who have not responded to traditional therapies. 

The conversation traces the origins of ketamine research to the pioneering clinical work conducted at Mount Sinai. The doctors explain how ketamine differs from standard antidepressants, why it can work within hours instead of weeks, and how it is helping patients with treatment-resistant depression and suicidal thinking.  

The panel also discusses:  

• How ketamine became the FDA-approved treatment Spravato 
• Why researchers believe ketamine increases neuroplasticity in the brain 
• The growing evidence for ketamine in treating PTSD 
• How psychotherapy may enhance ketamine’s long-term effects 
• Why patients should not lose hope, even after years of severe symptoms 

To learn more about Mount Sinai’s Depression and Anxiety Center or to book an appointment with a Mount Sinai expert, visit the Mount Sinai Health System’s website: https://icahn.mssm.edu/research/depression-anxiety-center 

🎧 Subscribe to The Vitals and explore more podcast programming from Mount Sinai for expert conversations on the biggest issues in medicine, research, and patient care: https://www.youtube.com/playlist?list=PLCT7BA-HcHliU8QIXyuk_74L_uH0gyKGt

If this episode inspired you, please consider supporting the Mount Sinai Health System. As a registered 501(c)(3) nonprofit, we rely on philanthropy to advance compassionate patient care, groundbreaking research, and medical education. Your generosity helps make conversations like this possible—and fuels the work behind them. To learn more or make a gift, visit give.mountsinai.org.